As pacing strategies continue to evolve toward lifelong patient management, AVEIR™ Leadless Pacemakers (LPs) offer a modular, leadless approach designed to adapt to changing clinical needs while minimizing lead burden. By enabling tailored therapy and supporting a leadless-first strategy associated with fewer complications and reinterventions, AVEIR LPs are helping redefine the future of cardiac pacing.
Pacing for a Lifetime: A New Philosophy in the Leadless Era
Abbott Cardiac Rythm Management | June 2, 2026
For decades, pacing decisions have appropriately balanced immediate clinical need with anticipation of future conduction disease and the need to preserve physiologic pacing. The 2026 HRS Expert Consensus Statement on Cardiovascular Implantable Electronic Device (CIED) Lead Management and Extraction builds on this foundation and reframes pacing as a lifetime management strategy.¹ As patients live longer and undergo multiple device‑related procedures, the cumulative burden of intravascular hardware, particularly transvenous leads, emerges as a major determinant of long‑term outcomes. Each lead implanted today shapes future options for revision, upgrade, and extraction. The evolving pacing paradigm is therefore not about favoring one technology over another, but about optimizing sustained clinical benefit through strategies designed for longevity, flexibility, and lifetime patient care.
The consensus statement reinforces a consistent finding across decades of evidence that transvenous leads are the primary source of complications across the CIED continuum. Mechanical failure, venous obstruction, infection, tricuspid valve dysfunction, and extraction‑related morbidity are fundamentally lead‑driven. As a result, lead management is central to device strategy and not a secondary consideration.
Within this framework, leadless and non‑vascular devices have transitioned from niche alternatives to routine considerations. For the first time, an expert consensus document formally ushers leadless technologies into firstline care. Discussion of all pacing options prior to implant is supported by a Class I recommendation, emphasizing shared decision‑making and a patient‑centric approach. Leadless pacing is no longer relegated to exceptional scenarios such as prior infection or limited venous access—it now belongs in the initial device conversation for all patients, moving from a reactive to a proactive pacing strategy.
A consistent principle across the consensus statement is that reducing lead burden reduces the need for future interventions. Lower lead burden is associated with lower reintervention rates, fewer pocket-related complications, preserved venous access, and reduced infection risk. This is most evident in infection management, where leadless pacing carries a Class I recommendation following system extraction in pacing-dependent patients, directly addressing the risk of reinfection by eliminating both the pocket and intravascular hardware.
This strategy is further reinforced in patients with tricuspid valve disease. Transvenous leads complicate transcatheter interventions, risk lead jailing, and increase extraction complexity. The guideline emphasizes proactive lead management before valve interventions and positions leadless pacing as a means to avoid lead–tricuspid valve issues altogether.
Taken together, the message is clear: minimizing lead burden helps preserve future options and reduce cumulative risk, shifting pacing from a single device decision to a longitudinal management strategy. With evolving guidelines and growing clinical experience, pacing strategies should move beyond default historical paradigms and toward contemporary approaches designed for durable, lifetime patient benefit.
™ Indicates a trademark of the Abbott group of companies.
‡ Indicates a third-party trademark, which is property of its respective owner.
Bluetooth and Bluetooth logo are registered trademarks of Bluetooth SIG, Inc.
Reference
- Cha YM, El‑Chami MF, Liu CF, et al. 2026. HRS/AHA/APHRS/EHRA/IDSA/LAHRS/PACES/STS Expert Consensus Statement Update on Cardiovascular Implantable Electronic Device Lead Management and Extraction. Heart Rhythm. 2026.
MAT-2675489 v1.0